Sudeep Pharma Analyst Review May 2026

This Sudeep Pharma analyst review for May 2026 covers all critical data investors need for SUDEEPPHRM at Rs 696.80. Sudeep Pharma is a pharmaceutical API manufacturer. This Sudeep Pharma analyst review analyses technical levels, business fundamentals, valuation, and key risks for SUDEEPPHRM through FY27.

Click Here – Get Free Investment Predictions

Sudeep Pharma Analyst Review: Company Snapshot May 2026

Sudeep Pharma produces active pharmaceutical ingredients for regulated and semi-regulated markets. The table below summarises key metrics for this Sudeep Pharma analyst review.

Parameter	Value
NSE Ticker	SUDEEPPHRM
Sector	Pharmaceuticals – APIs
CMP (May 2026)	Rs 696.80
52 Week High	Rs 766.45
52 Week Low	Rs 627.15
Market Cap	Rs 3500 Crore
Trailing P/E	35x
Analyst Consensus Target	Rs 871.00
Bull Case Target	Rs 1080.04
Bear Case Target	Rs 592.28

Analyst Insight: Sudeep Pharma Analyst Review for FY27

Senior Research Analyst Ankit Jaiswal flags Sudeep Pharma as a stock to watch in May 2026. At Rs 696.80, Ankit Jaiswal identifies key support in the Rs 639.69 to Rs 661.96 band and resistance near Rs 738.61. He suggests watching Sudeep Pharma for a potential move toward Rs 871.00. Ankit Jaiswal’s view in this Sudeep Pharma analyst review does not constitute a trade recommendation.

Technical Analysis in This Sudeep Pharma Analyst Review

This Sudeep Pharma analyst review places SUDEEPPHRM at Rs 696.80 within its 52-week band of Rs 627.15 to Rs 766.45. The 14-day RSI, MACD signal, and volume profile are key technical inputs when evaluating SUDEEPPHRM.

The Sudeep Pharma analyst review identifies support in the Rs 639.69 to Rs 661.96 range and resistance in the Rs 738.61 to Rs 783.90 zone. A sustained close above Rs 738.61 could signal momentum toward the analyst consensus target of Rs 871.00.

Screen the best stocks on the Univest Screener.

Support and Resistance in This Sudeep Pharma Analyst Review

• Support Zone: Rs 639.69 to Rs 661.96 – this Sudeep Pharma analyst review identifies this as a potential accumulation signal for SUDEEPPHRM.
• Resistance Zone: Rs 738.61 to Rs 783.90 – the Sudeep Pharma analyst review flags a close above Rs 738.61 as a positive signal for SUDEEPPHRM.
• Consensus Target: Rs 871.00 is the base-case target in this Sudeep Pharma analyst review.

Business Segments in This Sudeep Pharma Analyst Review

API Manufacturing for Regulated Markets

This primary segment drives revenue and margin for Sudeep Pharma, supporting the earnings trajectory toward Rs 871.00 in this Sudeep Pharma analyst review.

Specialty Pharma Ingredients

This segment adds meaningful scale to Sudeep Pharma’s model and is a key EPS contributor through FY27 as identified in this Sudeep Pharma analyst review.

Export to Global Pharma Companies

This growth frontier is a potential re-rating catalyst for SUDEEPPHRM and a key element of this Sudeep Pharma analyst review.

Valuation: Sudeep Pharma Analyst Review Bull Bear Base Case

At Rs 696.80 and P/E of 35x, this Sudeep Pharma analyst review sets three scenarios: bull case Rs 1080.04, base case Rs 871.00, and bear case Rs 592.28.

Scenario	Target Price	Key Condition
Bull Case	Rs 1080.04	Strong FY27 delivery and Pharmaceuticals – APIs re-rating
Base Case	Rs 871.00	Moderate growth per analyst consensus in this Sudeep Pharma analyst review
Bear Case	Rs 592.28	Earnings miss or macro headwinds for SUDEEPPHRM

FY27 Outlook in This Sudeep Pharma Analyst Review

This Sudeep Pharma analyst review for FY27 is constructive provided SUDEEPPHRM delivers on earnings expectations. Q1 FY27 results will be the first checkpoint. Investors should monitor Pharmaceuticals – APIs indicators, RBI policy, and FII flow trends.

Key Risks in This Sudeep Pharma Analyst Review

This Sudeep Pharma analyst review identifies four key risks for SUDEEPPHRM: macro slowdown, input cost pressure, FII selling, and Q1 FY27 earnings disappointment.

Download the Univest iOS App or the Univest Android App to get daily stock recommendations and expert research.

Conclusion: Sudeep Pharma Analyst Review Verdict May 2026

This Sudeep Pharma analyst review concludes that SUDEEPPHRM at Rs 696.80 presents a defined risk-reward with consensus target Rs 871.00. The 52-week range of Rs 627.15 to Rs 766.45 provides further context. Use this Sudeep Pharma analyst review as a research reference and consult a SEBI-registered advisor before investing in SUDEEPPHRM.

FAQs: Sudeep Pharma Analyst Review 2026

What is the analyst target for Sudeep Pharma in 2026?

The Sudeep Pharma analyst review consensus target is Rs 871.00, bull case Rs 1080.04, bear case Rs 592.28.

Is Sudeep Pharma a good buy at Rs 696.80?

At Rs 696.80 with PE 35x and target Rs 871.00, this Sudeep Pharma analyst review is constructive for 12-month investors. Consult a SEBI-registered advisor before acting on this Sudeep Pharma analyst review.

What is the 52-week high and low of Sudeep Pharma?

52-week high is Rs 766.45 and 52-week low is Rs 627.15. This Sudeep Pharma analyst review contextualises SUDEEPPHRM at Rs 696.80 within this range.

What are the key risks for Sudeep Pharma?

Key risks in this Sudeep Pharma analyst review: macro slowdown, input cost pressure, FII selling, and competitive pressure in the Pharmaceuticals – APIs sector.

Where can I track live data for Sudeep Pharma?

Track Sudeep Pharma’s live price on the Univest Screener to complement this Sudeep Pharma analyst review with real-time data.

Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice. Please consult a SEBI-registered financial advisor before making any investment decisions.